MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation Operating Cycle 2011-2026 | NRC
Annual Operating Cycle National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 | 29.9 | 33 | 33.9 | 34.1 | 35 | 33.4 | 37.4 | 47.1 | 41.5 | 40.7 | 38.4 | 49.6 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.6 | 29.4 | 37.2 |
Quarterly Operating Cycle National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.2 | 31.8 | 30.4 | - | 26.9 | - | - | - | 31.7 | 32.9 | 35.9 | - | 18.6 | 19.5 | 35.2 | - | 36.8 | 35.6 | 36.3 | - | 38 | 40.8 | 34.4 | - | 32.7 | 33.8 | 34.1 | - | 36.2 | 38.8 | 39.3 | - | 46.7 | 47.5 | 38.7 | - | 36.7 | 38 | 33.8 | - | 35.5 | 36.6 | 31.1 | - | 31.3 | 30.9 | 33.6 | - | 45 | 45.1 | 42.4 | - | 51.7 | 53.6 | 47.5 | - | 55 | 55.7 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 | 18.6 | 37.4 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
161 | $ 115.35 | -2.33 % | $ 35.1 B |  USA |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.81 | -2.7 % | $ 91.2 K | USA |
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
73.8 | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
275 | $ 22.48 | -1.58 % | $ 234 M |  China |
 |
Bioventus
BVS
|
259 | $ 8.45 | -7.14 % | $ 563 M | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 27.23 | -2.44 % | $ 756 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 175.23 | -3.37 % | $ 8.69 B | USA |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
405 | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 14.59 | 2.41 % | $ 441 M | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 18.61 | 17.37 % | $ 2.41 B | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
198 | $ 124.76 | -2.71 % | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 175.33 | -1.8 % | $ 30.1 B | USA |
 |
BioNano Genomics
BNGO
|
329 | $ 1.11 | -1.36 % | $ 1.41 M | USA |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
54.2 | $ 199.8 | -2.07 % | $ 22.2 B | USA |
 |
Danaher Corporation
DHR
|
143 | $ 195.75 | -2.99 % | $ 140 B | USA |
 |
IDEXX Laboratories
IDXX
|
128 | $ 607.19 | -1.9 % | $ 48.8 B | USA |
 |
Exact Sciences Corporation
EXAS
|
91.7 | $ 103.5 | 0.17 % | $ 19.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
251 | $ 9.69 | -3.0 % | $ 275 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
71.8 | $ 269.52 | -2.34 % | $ 22.4 B | USA |
 |
DexCom
DXCM
|
202 | $ 68.5 | -3.1 % | $ 26.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
172 | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 107.08 | -3.19 % | $ 8.83 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
121 | $ 72.86 | -4.53 % | $ 4.92 B | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.91 | -4.48 % | $ 954 M | USA |
 |
Chembio Diagnostics
CEMI
|
164 | - | 0.22 % | $ 16.8 M | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 215.85 | -3.66 % | $ 25.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
95.1 | $ 5.15 | 0.29 % | $ 477 M | USA |
 |
NeoGenomics
NEO
|
102 | $ 8.92 | -2.3 % | $ 1.14 B | USA |
 |
Guardant Health
GH
|
128 | $ 91.56 | -1.1 % | $ 11.5 B | USA |
 |
Natera
NTRA
|
81.5 | $ 196.94 | -0.1 % | $ 19.4 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
OPKO Health
OPK
|
285 | $ 1.18 | 0.43 % | $ 819 M | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |